Axe Compute Inc. Q4 FY2023 earnings call

• The company underwent restructuring and repositioning over the past year, making progress in leveraging assets like intellectual property and the PEDAL platform.
• Engaged with CRH to evaluate preclinical glutaminase inhibitor drug compounds, identifying responsive patient subpopulations across multiple tumor types.
• Collaborated with UPMC Magee-Women’s Hospital on a study predicting ovarian cancer survival, with potential applications in clinical decision support and trial design.
• Made progress with Cvergenx on precision radiation therapy and drug discovery, and with FluGen on a flu vaccine project (Phase 2B grant awarded).
• Plan to co-market endotoxin detection and treatment technologies with Fuji.
• Participated in investor conferences in 2024 to raise awareness.

In 2023, Predictive Oncology recorded revenue of $1.8 million. The Eagan operating segment contributed $1.135 million (approximately 63.06% of total revenue), and the Pittsburgh operating segment contributed $493,000 (approximately 27.39% of total revenue). Cash and cash equivalents at the end of 2023 were $8.7 million, down from $22.1 million in 2022. Stockholders' equity was $8.3 million in 2023, compared to $21.8 million in 2022.

No specific upward or downward revision of financial guidance was provided; the focus was on ongoing progress and leveraging partnerships to drive future growth.

Actual future performance may materially differ from forward-looking statements due to various factors, including those discussed in the company's SEC filings under Risk Factors. No specific operational failures were discussed in detail during the call.

Q: A: Q: A: